Affiliation:
1. University of Rwanda
2. Muhimbili University of Health and Allied Sciences
3. Ocean Road Cancer Institute
Abstract
Abstract
Background
Febrile Neutropenia (FN) caused by bacteria in cancer patients is associated with poor prognosis. The aim of this study was to determine the prevalence of FN and associated factors among cancer patients on chemotherapy at Ocean Road Cancer Institute (ORCI), Tanzania.
Methods
A cross-sectional study was conducted from June to September 2019. Study participants were conveniently recruited. A desk review of participants medical records was performed. Standard microbiological procedures used to culture and identify the bacterial isolates from the positive blood cultures of participants that presented with FN. Kirby-Bauer disc diffusion was used to perform the antibiotics susceptibility testing. SPSS version 20.0 and MS Excel were used in data entry and analysis. Chi-Square was used as a measure of association between various factors and neutropenia. P-Value less than 0.05 was considered statistically significant.
Results
A total 213 participants were enrolled. Of these 76.1% were female. Most of the participants came from the Coast region. Majority of participants presented with breast Cancer (36.2%) and GIT (20.2%). The prevalence of FN and bacteremia was 5.6% and 35.3% respectively. Staphylococcus Aureus (60%) and Coagulase-Negative Staphylococci (40%) were the main isolates. Of the 6 isolates tested most were resistant to Co-Trimoxazole 4/6 (66.7%) and Doxycycline 3/6 (50%). FN was positively associated with chemotherapy regimen (P = 0.0001), platelets count (P = 0.0001) and use of G-CSF (P = 0.0001).
Conclusion
The prevalence of FN among the cancer patients on chemotherapy in Tanzania
Publisher
Research Square Platform LLC
Reference54 articles.
1. Febrile Neutropenia in Cancer Patient: Epidemiology, Microbiology, Pathophysiology and Management;Rasmy A;J Cancer Prev Curr Res,2016
2. Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010 Dec 1;116(23):5555–63. http://doi.wiley.com/10.1002/cncr.25332.
3. Bloodstream infections in neutropenic cancer patients: A practical update;Mikulska GG;Virulence,2016
4. Prevalence of multidrug-resistant Gram-negative pathogens isolated from febrile neutropenic cancer patients with bloodstream infections in Egypt and new synergistic antibiotic combinations;Tohamy ST;Infect Drug Resist,2018
5. Carmona-Bayonas A, Jiménez-Fonseca P, Echaburu JV, Antonio M, Font C, Biosca M et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015 Feb 10;33(5):465–71. http://ascopubs.org/doi/10.1200/JCO.2014.57.2347.